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Abstract
Background: Research suggests that the COMT Val
158Met, BDNF Val
66Met and OPRM1 A
118G polymorphisms moderate the
experience of pain. In order to obtain experimental confirmation and extension of findings, cortical processing of
experimentally-induced pain was used.
Method: A sample of 78 individuals with chronic low back pain complaints and 37 healthy controls underwent EEG
registration. Event-Related Potentials were measured in response to electrical nociceptive stimuli and moderation by COMT
Val
158Met, BDNF Val
66Met and OPRM1 A
118G polymorphisms was assessed.
Results: Genetic variation did not have a direct effect on cortical processing of experimental pain. However, genetic effects
(COMT Val
158Met and BDNF Val
66Met) on experimental pain were moderated by the presence of chronic pain. In the
presence of chronic pain, the COMT Met allele and the BDNF Met allele augmented cortical pain processing, whilst reducing
pain processing in pain-free controls. No significant effects were found concerning the OPRM1 A
118G polymorphism.
Conclusions: The current study suggests that chronic experience of pain enhances genetic sensitivity to experimentally
induced mildly painful stimuli, possibly through a process of epigenetic modification.
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Introduction
The experience of pain is subject to individual differences
resulting from psychological factors, behavioral factors and
biological factors [1–4]. There is rising interest in genetic factors,
as these likely explain a substantial portion of the inter-individual
differences in pain responses [5]. Studies using genetically
modified mice have proposed a large number of candidate ‘pain
genes’[6]. In human studies, however, the list to date is much
shorter. In particular, three single nucleotide polymorphisms
(SNPs) have been proposed to impact on pain perception; COMT
Val
158Met (rs4680), BDNF Val
66Met (rs6265) and the OPRM1
A
118G (rs1799971) [7–9].
Catechol-O-Methyl Transferase (COMT) is an enzyme that
catabolizes catecholamines and thus influences the dopaminergic
and adrenergic/noradrenergic neurotransmission[10]. The
COMT Val
158Met polymorphism codes a valine (val) to metionine
(met) substitution at codon 158, resulting in decreased thermosta-
bility of the COMT protein. The val158met polymorphism alters
the in-vivo activity of the COMT enzyme; Val/Val homozygotes
have higher levels of the COMT enzyme and correspondingly
lower levels of D2 receptor neurotransmission leading to a higher
level of activation of the m-opioid system [11,12]. On the other
hand, Met/Met homozygotes have lower levels of the COMT
enzyme activity, resulting in increased dopaminergic neurotrans-
mission. COMT activity alterations associated with Val
158Met
impacts on responsiveness of the m-opioid system, which is
activated in response to pain and stressors, and typically reduces
pain and response to stress [13,14]. Met/Met homozygotes have
decreased m-opioid system activation in response to pain [15].
Therefore, Met/Met homozygotes are believed to be more
sensitive to nociceptive stimuli than heterozygotes or Val/Val
homozygotes.
Brain Derived Neurotrophic Factor (BDNF) is a neurotrophin
that supports the growth, differentiation and survival of neurons in
both the peripheral and the central nervous system. BDNF is
released when nociceptors are activated and is involved in the
activity-dependent pathogenesis of nociceptive pathways that may
lead to chronification of pain. A genetic variation within the
BDNF genes results in a valine to metionine substitution at codon
66 (Val
66Met), resulting in reduced secretion of the BDNF protein
and impaired BDNF signaling. The BDNF Val66Met polymor-
phism may be implicated in depression and is also hypothesized to
influence pain mechanisms [16,17]. Despite the hypothesized
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66Met polymorphism on pain, an online search
in PubMed (http://www.ncbi.nlm.nih.gov/pubmed) with ‘BDNF
Val
66Met’ and ‘pain’ as keyword did not result in any publications.
The A
118G polymorphism of the m-Opioid Receptor 1(OPRM1)
gene replaces adenine with guanine, increasing the receptor affinity
of b-endorphin three-fold [18,19]. It is hypothesized to increase the
activity of the endogenous opioid system, which could be associated
with a decreased response to nociceptive stimulation [20]. The
theory that this gene polymorphism influences pain mechanisms
comes mainly from mice studies reporting that opioid receptor
knock-out mice had increased nociceptive responsiveness [21]. In
human studies, the OPRM1 118G allele may increase the dose of
morphine needed to achieve pain control [22,23]. Furthermore, a
study by Fillingim and co-workers (2005) reported that G allele
carriers (infrequent allele) had significantly higher pressure pain
thresholds than A allele homozygotes [18]. Lo ¨tsch and colleagues
(2006) studied the influence of the G allele on cortical pain
processing of experimental pain stimuli [20]. They concluded that
ERP amplitudes (N1 component) of carriers of the G allele were, on
average, half as high as the amplitude of the non-carriers,suggesting
a lower pain processing for the G allele carriers.
The work described above yields a suggestion that several gene
polymorphisms may influence pain responsiveness and that further
work is required. It has been suggested that experimental designs
represent a particularly powerful approach for the study of genetic
effects on psychological phenotypes as they allow for controlled
conditions and investigation of underlying mechanisms [24]. In
pain research, Event Related Potentials (ERPs) are frequently used
as a more objective measure of pain, compared to subjective pain
ratings, elicited by controlled exposure to noxious stimuli [25].
Previous research has demonstrated positive correlations between
the amplitude of specific peak components and the intensity of the
pain stimulus, as well as between ERP amplitudes and subjective
pain ratings [26–29]. Especially, the P1, N2 and P2 components
are considered to be related to pain intensity. Thus, the aim of this
study was to investigate the influence of functional variation in
three gene polymorphisms on the cortical processing of experi-
mental pain as measured with Event-Related Potentials. Results
from previous studies demonstrate that the pain ERP to
experimental noxious stimuli is influenced by the presence of
chronic pain complaints [30–32]. Therefore, any influence of
genetic polymorphisms was assessed in interaction with clinical
pain disorder.
For every gene polymorphism two hypotheses were tested: (i)
Carriers of the infrequent allele (Met allele for COMT and BDNF,
and G allele for OPRM1) are expected to have different maximum
peak amplitudes on the pain-specific ERP components (N1, P1,
N2 and P2) in response to experimental pain stimuli compared to
non-carriers [27,33–35]. More specifically, concerning the COMT
Val
158Met polymorphism the Met allele carriers are expected to
have larger ERP peak amplitudes compared to the non-carriers.
For the BDNF Val
66Met polymorphism, Met allele carriers are
also expected to have larger amplitudes compared to the non-
carriers. For the OPRM1 A
118G, the G allele carriers are expected
to have reduced amplitudes compared to non-carriers. (ii) Genetic
effects are moderated by the experience of chronic pain. More
specifically, we expected significant interaction effects between the
polymorphisms and pain status (chronic low back pain patients
versus pain free controls).
Methods
Approval has been obtained from the medical ethics committee
of the Academic Hospital Maastricht (the Netherlands), on
January, 6th, 2005. All subjects gave their verbal and written
informed consent prior to the experiment.
Subjects
Two groups of subjects were included in this study. The first
group consisted of 78 subjects with low back pain complaints.
These subjects were drawn from the general population (via
advertisements, distributed door to door) and were required to
have low back pain for at least six months with no other interfering
pain complaints. before the experiment. The second group
consisted of 37 pain-free subjects. Exclusion criteria for both
groups were the use of psychoactive drugs in general and the use of
analgesics more than eight hours before the experiment.
Participation was rewarded with J25,-.
Stimuli
The stimuli used were electrical pulses of 10 ms duration,
administered intracutaneously on the left middle finger. For each
participant, five different intensities based on that participant’s
sensation and pain thresholds were administered. Of the five
intensities, one was equal to the pain threshold and the other four
were defined relative to this pain threshold, namely 250%,
225%, +25% and +50% of the threshold range which was defined
as the range between the sensation threshold and the pain
threshold. The sensation threshold was determined by first
administering stimuli at zero intensity and then gradually
increasing the intensity until the stimuli were experienced
consciously. Once experienced consciously (sensation threshold),
stimuli were once again administered with an intensity that
gradually increased from the sensation threshold until the stimuli
were defined as painful by the participant (pain threshold). This
procedure was repeated three times in order to generate a reliable
measurement.
Rating paradigm
The stimuli were presented using a rating paradigm [36]. The
paradigm consisted of 150 stimuli. The five intensities mentioned
above were presented semi-randomly (Every intensity was
presented 30 times in the paradigm). The inter-stimulus interval
(ISI) ranged from 9 to 11 seconds. Subjects were asked to verbally
rate each stimulus on a scale of 0 (no sensation) to 100 (most
excruciating pain imaginable).
EEG recording
All EEG recordings were conducted in an electrically- and
sound-shielded cubicle (3*4 m
2). Ag/AgCl electrodes were placed
on Fz, Cz, Pz, C3, C4, T3 and T4 using the international 10–20
system [37]. Impedances were kept below 5 kV. A reference
electrode was placed on each ear lobe. To control for possible
vertical eye movements, an electro-oculogram (EOG) electrode
was placed 1 centimetre under the midline of the right eye. A
ground electrode was placed at Fpz. All electrodes were fixed using
10–20 conductive paste. Neuroscan 4.3 software was used for EEG
recording.
Procedure
Before starting the experiment, subjects were informed about
the purpose of the study. Subjects were told that they would
undergo EEG-registration while receiving electric shocks. After
signing the informed consent form, EEG electrodes were placed
and the shock electrode was attached to the top of the left middle
finger as described by Bromm and Meier (1984): a small opening
in the upper layer of the skin was prepared using a dental gimlet
Genetics and Pain
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prepared opening, a platinum electrode was placed and fixed with
tape. Next, the sensation and pain threshold were determined and
after that, the rating paradigm was initiated.
Genetic analyses
Buccal cell samples were collected with sterile swabs (Omnis-
wab, WhatmanH). DNA was extracted using QIAamp DNA Mini
Kits (Qiagen). In total, seven SNPs within the COMT gene were
determined. The following three SNPs were genotyped using
TaqManH SNP Genotyping assays (Applied Biosystems): rs4680
(assay ID C__25746809_50), rs6265 (assay ID C__11592758_10),
and rs1799971 (assay ID C___8950074_1_). All assays were run
on a 7900HT Fast Real-Time PCR System (Applied Biosystems).
ERPs
EEG was recorded with 1000 Hz sampling rate, using
Neuroscan 4.3 software. Trials were selected from the continuous
EEG, from 200 ms prior to the stimulus until 1500 ms post-
stimulus. Data was offline filtered (bandpass 0–50 Hz) and baseline
corrected. Trials with EOG activity exceeding +75mA and
275mA were excluded from the analyses.
Statistical analyses
Multilevel random regression analyses were performed because
of the hierarchical structure of the ERP data [33,34]. The
hierarchical structure of the current ERP data consist of single
trials (level 1) that are clustered within individuals (level 2). This is
important because trials of one person are more correlated to each
other than trials for different persons. This regression technique
has previously proven to be useful in the study of the ERPs [35].
The following maximum peak components, N1 (20–55 msec), P1
(56–95 msec), N2 (96–145 msec), P2 (146–300 msec), served a
priori as dependent variable, as these components have consistently
been shown to be related to the processing of stimulus intensity
[27,36–40]. Only ERP amplitudes of the strongest intensity (50%
above the pain threshold) were used in the analyses. The N1 and
P1 components are considered to be involved with the sensory
processing and generated by activity in the primary and secondary
somatosensory cortices. The N2 and P2 components are thought
to be generated by neurons in the cingulate cortex, which is part of
the limbic system which in turn is responsible for the emotional
processing of pain stimuli [41]. Trial number, sensation threshold,
pain threshold, age, gender, pain status and intensity of the
previous stimulus served as independent variables in a basic
model. Trial number was included in order to investigate, as well
as correct, for difference over time (for instance habituation). It
was divided in a linear effect, a quadratic and an inverse effect
[35]. The sensation threshold and pain threshold were included in
the model to correct for individual differences in the absolute
intensities (mAmp) of the electrical stimuli that were presented.
Gender and age have previously been found to influence the ERP
so they were included in order to correct for their influences
[42,43]. The variable pain status refers to the chronic pain patients
versus pain free controls. Finally, the intensity of the previous
stimulus was included as a within-subject covariate to control for
intensity sequence effect which have proven to play an influence
[35]. All the independent variables, except for trial (inverse), were
centered (the sample mean was subtracted from each individual
score) [44].
In order to study the influences of the three gene polymor-
phisms they were first added (separately) as main factors to the
basic model. The polymorphisms were included in the analyses as
dichotomous variables (allele carriers and non-carriers). In order to
test the second hypothesis, interactions between pain status and
the gene polymorphisms were added.
Preliminary analyses proved that the Scaled Identity covariance
structure was the best fit for our dataset. The goodness of fit (-2
Log Likelihood) of that covariance structure was significantly
better than that of its competitors, namely compound symmetry
(CS) and AR1. Therefore the Scaled Identity structure was used in
the multilevel analyses. A random intercept was included to
correct for any baseline differences between individuals. All
statistical analyses were performed using SPSS 16.0. All p-values
#0.007 (two-tailed with Bonferroni correction for the number of
cranial locations, namely seven) were considered as statistically
significant. Effects were considered marginally significant when
p-values were between 0.050 and 0.008.
Results
Demographic and allele/genotype distributions are displayed in
table 1. Crosstabs revealed no significant difference in allelic
distribution between the healthy control group and chronic pain
group (COMT Met allele: p=0.167, BDNF Met allele: p=0.910
and OPRM1 G allele: p=0.815). The three polymorphisms were
in Hardy-Weinberg Equilibrium (x
2=1.129 p=0.288 for COMT,
x
2=0.210, p=0.650 for BDNF and x
2=0.555, p=0.555 for
OPRM1). Furthermore, there were no significant differences in
pain threshold between the Met carriers and Val homozygotes of
BDNF and COMT polymorphisms and the G allele carriers and
A homozygotes of the OPRM1 polymorphism.
The COMT Val
158Met gene polymorphism
The first hypothesis tested for a difference in cortical pain
processing between the COMT Met allele carriers and Val
homozygotes. The results showed that the COMT Met allele did
not directly explain variance of the pain ERP and therefore do not
support the first hypothesis.
The second hypothesis concerned a moderation of the effect of
the Met allele by chronic pain complaints (pain status). A significant
interaction between pain status (chronic pain patients vs. pain-free
controls) and the Met allele was found modeling the N2-component
of C4 (B=22.25, SE=0.61, p,0.001). Furthermore, a marginally
significant interaction was found at C3 (B=21.63, SE=0.65,
p=0.013) and T4 (B=22.28, SE=0.84, p=0.008). Figure 1
illustrates the interaction effect and shows that in the pain-free
control group, the COMT met carriers have lower maximum peak
amplitudes (less negative) compared to the Val homozygotes. In the
chronic pain group, the carriers have a higher maximum peak
amplitude (more negative) compared to the Val homozygotes.
The BDNF Val
66Met gene polymorphism
The results for the first hypothesis did not show any direct effect
of the BDNF Met allele on the pain ERP, indicating that there is
no difference in cortical pain processing between Met allele
carriers and Val homozygotes. Therefore the first hypothesis was
not supported.
Analyses investigating the moderating effect of chronic pain
complaints on the effect of the BDNF Met allele, revealed a
significant interaction between pain status and the BDNF Met
allele in the model of the P1- component of Fz (B=1.87,
SE=0.63, p=0.004), Cz (B=1.80, SE=0.54, p=0.001), Pz
(B=1.34, SE=0.46, p=0.004, C3 (B=1.66, SE=0.49,
p=0.001) and a marginally significant interaction in the model
of the P1-component of C4 (B=1.40, SE=0.55, p=0.013).
Figure 2 shows the interaction effect in the Cz models. Similar to
the results of COMT, in the pain-free control group the COMT
Genetics and Pain
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than the Val homozygotes. In the chronic pain group, Met carriers
had higher maximum peak amplitudes (more positive) than the
Val homozygotes.
The OPRM1 A
118G gene polymorphism
Similar to COMT Val
158Met and BDNF Val
66Met, no main
effect of the OPRM1 A
118G polymorphism on the pain ERP was
apparent. Carriers of the G allele thus did not respond
differentially to experimental nociceptive stimuli from A homozy-
gotes. Furthermore, no significant interactions were found for the
OPRM1 genotype and pain status.
Based on the knowledge that both the COMT Val
158Met and
the OPRM1 A
118G polymorphisms act on the mu-opioid system
[45], post-hoc analyses, in which both polymorphisms were
included in the model as main effects and in interaction with
each other, were performed to test whether these two polymor-
phisms interact with each other. The results showed no
moderation or mediation for these two polymorphisms. Further-
more, both COMT Val
158Met and BDNF Val
66Met polymor-
phisms have been shown to be involved in the development of
depressive disorders and, there is a well known interplay between
pain and depression. Post-hoc analyses revealed that individuals
with chronic pain complaints reported more depressive symptoms
(measured with the Beck Depression Inventory) compared to the
pain free controls (m=6.73 (4.37) for chronic pain patients and
m=3.02 (2.87) for pain free controls, (t-value =26.370, p,0.001).
However, correcting the analyses for this depression effect
(including the BDI score as a confounder in de multilevel
regression) did not change any of the result presented in this paper.
Discussion
The main goal of this study was to investigate the influence of
three ‘pain gene candidate polymorphisms’ (COMT Val
158Met,
BDNF Val
66Met and OPRM1 A
118G), on pain Event Related
Potentials. It was investigated whether these polymorphisms
Table 1. Demographic and genotypic data of the sample.
Chronic pain group (N=78) Pain free controls (N=37)
Demographic data
Gender (M/F) 38/40 16/21
Age in years, mean (SD) 40.4 (15.4) 36.1 (14.6)
Experimental data
Sensation threshold (mV), mean (SD) 0.3 (0.1) 0.2 (0.1)*
Pain threshold (mV), mean (SD) 1.1 (0.9) 0.8 (0.5)
Genotype distribution, n (%) Val/Val Val/Met Met/Met Val/Val Val/Met Met/Met
COMT Val
185Met 22 (28.6) 43 (55.8) 12 (15.6) 15 (41.7) 17 (47.2) 4 (11.1)
BDNF Val
66Met 54 (69.2) 22 (28.2) 2 (2.6) 26 (70.2) 9 (24.3) 2 (5.5)
OPRM1 A
118G 61 (80.3 13 (17.1) 2 (2.6) 29 (78.4) 8 (21.6) 0 (0)
Allele distribution, n (%) Carriers Noncarriers Carriers Noncarriers
COMT Met allele 55 (71.4) 22 (28.6) 21 (58.3) 15 (41.7)
BDNF Met allele 24 (30.8) 54 (69.2) 11 (29.7) 26 (70.3)
OPRM1 G allele 15 (19.7) 61 (80.3) 8 (21.6) 29 (78.4)
*P-value of independent sample t-test smaller than 0.05.
doi:10.1371/journal.pone.0013641.t001
Figure 1. Interaction between the COMT 158Met allele and pain status. Maximum peak amplitudes of the N2-component at C4. Note that
the y-axis displays negative numbers since this concerns a negative ERP component.
doi:10.1371/journal.pone.0013641.g001
Genetics and Pain
PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13641influenced the cortical processing of experimental pain and
whether the presence of clinical pain influences this.
The results demonstrate that the COMT Val
158Met polymor-
phism did not have a direct (main) effect on the pain ERP. In other
words, independent of the covariates (intensity, trial number,
sensation threshold pain status etc.), there was no difference in
cortical pain processing between Met allele carriers and Val
homozygotes. There was, however, an interaction between pain
status and the Met allele (N2-component of C4), indicating that
the effect of the COMT Met allele on the pain ERP was
moderated by the presence of chronic pain complaints. When
chronic pain complaints were present, COMT Met carriers
displayed stronger cortical pain processing of stimuli than the Val
homozygotes. When chronic pain complaints were absent, the
carriers displayed weaker pain processing compared to Val
homozygotes. Thus, in this study, the expected pain augmenting
effect of the COMT Met allele only occurred in a group of chronic
pain patients. In a pain-free population, the Met allele, if anything,
may have a beneficiary effect on the cortical processing of pain.
In regard to the BDNF Val
66Met polymorphism, the results
showed nodifferencesin cortical pain processing between Met carriers
and Val homozygotes. There was, however, again a significant
interaction between pain status and the Met allele at several locations.
Similar to the results of the COMT polymorphism, the interaction
between pain status and the BDNF Met allele indicated that when
chronic low back pain complaints were present, the Met allele carriers
displayed stronger ERP amplitudes (P1 component) compared to Val
homozygotes. When chronic pain complaints were not present, the
non-carriers displayed stronger amplitudes. Again, the hypothesized
pain augmenting effect of the BDNF Met allele only occurred when
chronic pain complaints were present.
The mu-opioid polymorphism OPRM1 A
118G was the only one
of the three selected polymorphisms that has previously been
studied with the use of Event-Related Potentials. Lo ¨tsch and
colleagues (2006) found that the G allele carriers had significantly
lower N1 peak amplitude compared to the non-carriers at Cz [20].
In the present study, however, such a significant effect of the G
allele was not found. This difference in result may be explained by
differences in pain stimulus (nasal CO2 stimulation vs. electrical
stimulation), stimulus duration (200 ms vs. 10 ms) and paradigm (2
intensities vs. 5 intensities). No significant interactions were found
between the OPRM1 genotype and clinical status.
Thus the results demonstrate that the presence of chronic pain
complaints moderates the influence of the COMT and the BDNF
polymorphisms on the cortical processing of experimental pain
stimuli. An explanation concerning the COMT Val
158Met
polymorphism might be alterations in endogenous opioid system
that is associated with chronic pain complaints [46]. Jensen and
colleagues (2009) reported that COMT Val
158Met differences may
be more expressed in individuals where the inhibitory nociceptive
system is already challenged and sensitive [47]. Furthermore, it is
tempting to speculate that epigenetic mechanisms play a role in
this. Chronic exposures to environmental factors may result in
dynamic changes of neuronal gene expression which may persist
over time but can also be reversed [48]. Future research is needed
to test this speculation.
The main limitation of this study most likely concerns the
relatively small number of healthy controls. Therefore only the
alleles and not the genotypes could be studied, precluding the
study of specific recessive or dominant models. Studying genotypes
could have given information about possible differences in cortical
processing of pain stimuli, between the heterozygotes and
homozygotes of the alleles of interest. For that reason, further
research with larger populations is needed for more power. In
addition stratified samples on genotype would result in an equal
distribution of genotype. Also, due to the study design it cannot be
entirely excluded that genetic influence on cortical processing of
experimental pain may also be shaped by different affective
processing between both groups. Finally, including neuroimaging
tools in further research would give more detailed information on
which brain areas are influenced by these polymorphisms, since
Event-Related Potentials have poor spatial resolution.
The current study gives evidence that the COMT Val
158Met and
the BDNF Val
66Met polymorphisms influence the cortical
processing of experimental electrical pain stimuli, however not in
a direct manner but rather under moderation of the presence of
chronic pain complaints. This influence of chronic pain complaints
on gene expression possibly implicates epigenetic modification.
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